Skip to main content
. 2020 Aug 8;28(12):2553–2563. doi: 10.1016/j.ymthe.2020.08.005

Figure 2.

Figure 2

Delivery of CXCL9 and OX40L by AT-MSCs Leads to Tumor Regression

(A and B) CT26 (A) and MC38 (B) tumors were established subcutaneously. 0.5 × 106 MSC-Vec, MSC-C9 (CXCL9), MSC-T4 (OX40L), MSC-C9 × T4 cells, or PBS was administered by i.v. injection every 4 days for a total of four times. Tumor growth was recorded over time (n = 6 mice per group).